Detalles de la búsqueda
1.
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Haematologica
; 108(7): 1793-1802, 2023 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36779592
2.
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Lancet Oncol
; 19(6): 812-824, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29706375
3.
An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.
Clin Transl Sci
; 14(6): 2300-2313, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34405542
4.
The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
Biomedicines
; 9(6)2021 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34200749
5.
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Nat Med
; 26(9): 1459-1467, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32601337
6.
Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
Thromb Haemost
; 98(6): 1237-45, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18064320
7.
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
JCO Precis Oncol
; 6: e2200006, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36331248
8.
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study.
Transplantation
; 74(12): 1725-34, 2002 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-12499889
Resultados
1 -
8
de 8
1
Próxima >
>>